BioPharma Dive December 16, 2025
The gene therapy developer has lost most of its value since going public in 2020 and saw a long road ahead for a delivery technology that had shown promise in preclinical tests.
Xoma Royalty, which has recently built a business out of acquiring struggling biotechnology companies, has secured its latest target.
In announcement late Monday, Xoma said it has agreed to pay about $4.29 per share to acquire Generation Bio, a gene therapy developer that’s currently worth less than its cash holdings.
The per-share acquisition price is lower than Generation’s $5.39 closing price on Monday. But Generation’s shareholders will also receive a so-called contingent value right making them eligible to receive additional payments. Among those possible payouts are a share...
Today's Sponsors
Today's Sponsor